Navigation Links
BioMS Medical to participate in panel session at Bio International Convention 2009
Date:5/14/2009

is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for Secondary Progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical Announces First quarter 2009 results
2. BioMS Medical to present at Alberta Economic Forum in Geneva
3. BioMS Medical to present at BioFinance 2009
4. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
5. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
6. BioMS Medical Announces 2008 Year End Results
7. BioMS Medical warrant extension
8. BioMS Medical to present at BIO CEO and Investor Conference
9. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
10. BioMS Medical recognized at Scrip Awards 2008
11. BioMS Medical Announces Third Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... The discovery 30 years ago of soccer-ball-shaped carbon molecules ... research. Now, there appears to be a new ball ... University and Tsinghua University in China have shown that ... molecular cage similar to a carbon buckyball. It,s the ... a matter of speculationdoes indeed exist. , "This is ...
(Date:7/11/2014)... DUBLIN , July 11, 2014 ... "International Transfection Technology Market - Global Industry Analysis, ... report to their offering. ... to introduce nucleic acids (either DNA or RNA) into ... therapy, mutation of cancer cells and protein metabolism by ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Cayenne ... company specializing in the soft tissue reconstruction segment, ... Anchor System for surgeries involving the shoulder and ... through a novel, inserter-controlled deployment method. The unique ... partial deployment, anchor pull-out, or anchor displacement (also ...
(Date:7/10/2014)... Terascala, the industry leader in HPC ... former vice president of product management for Flexera Software, ... marketing. Terascala’s software when combined with leading compute and ... performance and most reliable solutions for processing big data. ... expansion and broaden its product portfolio. His leadership in ...
Breaking Biology Technology:Researchers discover boron 'buckyball' 2Researchers discover boron 'buckyball' 3International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Terascala Expands Executive Team 2Terascala Expands Executive Team 3
... Madison, Wis. - CDW Corp. , a $6 ... Hills, Ill., has agreed to acquire the stock of Madison-based ... cash. , ,The acquisition, which has been approved by ... the end of October, subject to regulatory approvals and approval ...
... Madison, Wis. - Not everyone is a fan ... most up-to-date technology - fiber to the premises. , ... the pack with trailing-edge technology is pervasive, but ... a different calculation. , ,TDS has introduced its Symmetrical ...
... Stem Cell Bank has announced it will receive human ... , giving it 13 of the 21 stem cell lines ... of the WiCell Research Institute , which houses the ... eventually will have all 21 federally approved lines. , ,"We're ...
Cached Biology Technology:Berbee believes acquisition by CDW will make it a national IT player 2Berbee believes acquisition by CDW will make it a national IT player 3TDS believes faster DSL service will suit small businesses 2Nation's only stem cell bank will receive UC-San Francisco cell line 2
(Date:7/11/2014)... addition to the hippocampus, the marginal division of ... memory. What is the impact degree of substance ... and memory function? Yan Yu and his team, ... found, using immunofluorescence staining, that substance P receptor, ... and striatal marginal division of normal rats. Unilateral ...
(Date:7/11/2014)... type 1 can inhibit voltage-gated calcium channel, ... release. However, some scholars demonstrated that cannabinoid ... influx and increase neurotransmitter release. Dr. Yi ... to Tongji Medical College, Huazhong University of ... voltage-clamp and calcium imaging in cultured trigeminal ...
(Date:7/11/2014)... spider toxins to study the proteins that let nerve ... they have stumbled upon a biological tactic that may ... plagues in a safe and environmentally responsible way. ... lethal for one species and harmless for a closely ... specific pests without harming beneficial species like bees. A ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3
... a human hair to deliver drugs to cells or assist ... of a science fiction movie, but these scenarios may be ... Carbon nanotubes, cylindrically shaped carbon molecules with a diameter of ... of fields, such as biomedical engineering and medical chemistry. ...
... The National Institutes of Health (NIH) has awarded ... University and PATH, a Seattle-based nonprofit organization, to advance ... using patches containing tiny microneedles that dissolve into the ... address key technical issues and advance the microneedle patch ...
... Elsevier ( www.elsevier.com ) , a world-leading ... and services, today announced the launch of SciVerse ... platform that will empower the scientific community to ... search and discovery process through its marketplace and ...
Cached Biology News:Nanotechnology: A dead end for plant cells? 2NIH awards $10 million to advance microneedle patch for flu vaccination 2NIH awards $10 million to advance microneedle patch for flu vaccination 3NIH awards $10 million to advance microneedle patch for flu vaccination 4Elsevier launches SciVerse Applications beta 2Elsevier launches SciVerse Applications beta 3
Biotin-OSu is used to label proteins, immunological agents, DNA and synthetic oligonucleotides. Biotin labeling is detected through enzymatically labeled avidin or streptavidin proteins that conforma...
Cross reactivity to St. Louis encephalitis (MSI-7) is determined by ELISA....
ANTI K. AEROGENES...
casein kinase 2, alpha 1 polypeptide, transcript variant 2, mRNA (cDNA clone MGC:15232 IMAGE:4121882), complete cds...
Biology Products: